Age-specific predictors of disease severity in children with respiratory syncytial virus infection beyond infancy and through the first 5 years of age.
RSV
children
clinical outcomes
disease severity
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
16
01
2024
received:
02
08
2023
accepted:
19
01
2024
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
16
2
2024
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) infection is associated with significant morbidity in infants. Risk factors for severe disease beyond the first 2 years of life have not been fully defined. Children <5 years hospitalized with virologically confirmed RSV infection were identified over six respiratory seasons (10/2012-4/2018) and their medical records manually reviewed. Multivariable analyses were performed to define the age-specific (<6, 6-24, and >24-59 months) risk factors associated with oxygen administration, PICU admission, mechanical ventilation, and duration of hospitalization. We identified 5143 children hospitalized with RSV infection: 53.5% (n = 2749) <6 months; 31.7% (n = 1631) 6-24 months; and 14.8% (n = 763) >24-59 months. Rates of ICU admission were high (35%-36%) and comparable across age groups, while children >24-59 and 6-24 versus those <6 months required supplemental oxygen more frequently (73%; 71%; 68%, respectively; p = .003). The presence of comorbidities increased with age (25%, <6 months; 46%, 6-24 months; 70%, >24-59 months; p < .001). Specifically, neuromuscular disorders, chronic lung disease, and reactive airway disease/asthma were predictive of worse clinical outcomes in children aged 6-24 and >24-59 months, while RSV-viral codetections increased the risk of severe outcomes in children aged <6 and 6-24 months of age. Almost half of children hospitalized with RSV infection were >6 months. Underlying comorbidities increased with age and remained associated with severe disease in older children, while RSV-viral codetections were predictive of worse clinical outcomes in the youngest age groups. These data suggest the importance of defining the clinical phenotype associated with severe RSV according to age, and the persistent burden associated with RSV beyond infancy.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory syncytial virus (RSV) infection is associated with significant morbidity in infants. Risk factors for severe disease beyond the first 2 years of life have not been fully defined.
METHODS
METHODS
Children <5 years hospitalized with virologically confirmed RSV infection were identified over six respiratory seasons (10/2012-4/2018) and their medical records manually reviewed. Multivariable analyses were performed to define the age-specific (<6, 6-24, and >24-59 months) risk factors associated with oxygen administration, PICU admission, mechanical ventilation, and duration of hospitalization.
RESULTS
RESULTS
We identified 5143 children hospitalized with RSV infection: 53.5% (n = 2749) <6 months; 31.7% (n = 1631) 6-24 months; and 14.8% (n = 763) >24-59 months. Rates of ICU admission were high (35%-36%) and comparable across age groups, while children >24-59 and 6-24 versus those <6 months required supplemental oxygen more frequently (73%; 71%; 68%, respectively; p = .003). The presence of comorbidities increased with age (25%, <6 months; 46%, 6-24 months; 70%, >24-59 months; p < .001). Specifically, neuromuscular disorders, chronic lung disease, and reactive airway disease/asthma were predictive of worse clinical outcomes in children aged 6-24 and >24-59 months, while RSV-viral codetections increased the risk of severe outcomes in children aged <6 and 6-24 months of age.
CONCLUSIONS
CONCLUSIONS
Almost half of children hospitalized with RSV infection were >6 months. Underlying comorbidities increased with age and remained associated with severe disease in older children, while RSV-viral codetections were predictive of worse clinical outcomes in the youngest age groups. These data suggest the importance of defining the clinical phenotype associated with severe RSV according to age, and the persistent burden associated with RSV beyond infancy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14083Subventions
Organisme : NIH UM1TR004548
Organisme : Janssen Pharmaceuticals
Informations de copyright
© 2024 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2019;222(Suppl 7):S577-S583.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095-2128.
Pneumonia Etiology Research for Child Health Study G. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394(10200):757-779.
Garcia CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010;126(6):e1453-e1460.
Muller WJ, Madhi SA, Seoane Nunez B, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 2023;388(16):1533-1534.
Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464.
Antillon M, Li X, Willem L, et al. The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: a semi-parametric, meta-regression approach. PLoS Med. 2023;20(7):e1004250.
Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-2064.
Hartmann K, Liese JG, Kemmling D, et al. Clinical burden of respiratory syncytial virus in hospitalized children aged ≤5 years (INSPIRE study). J Infect Dis. 2022;226(3):386-395.
Halabi KC, Wang H, Leber AL, Sanchez PJ, Ramilo O, Mejias A. Respiratory syncytial virus and SARS-CoV-2 coinfections in children. Pediatr Pulmonol. 2022;57(12):3158-3160.
Garcia-Maurino C, Moore-Clingenpeel M, Thomas J, et al. Viral load dynamics and clinical disease severity in infants with respiratory syncytial virus infection. J Infect Dis. 2019;219(8):1207-1215.
Wang X, Li Y, Vazquez Fernandez L, et al. Respiratory syncytial virus-associated hospital admissions and bed days in children <5 years of age in 7 European countries. J Infect Dis. 2022;226:S22-S28.
Reeves RM, Hardelid P, Gilbert R, Warburton F, Ellis J, Pebody RG. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012. Influenza Other Respi Viruses. 2017;11(2):122-129.
Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015;5(2):020416.
Moyes J, Tempia S, Walaza S, et al. The economic burden of RSV-associated illness in children aged <5 years, South Africa 2011-2016. BMC Med. 2023;21(1):146.
Rha B, Curns AT, Lively JY, et al. Respiratory syncytial virus-associated hospitalizations among young children: 2015-2016. Pediatrics. 2020;146(1):e20193611.
Jalink MB, Langley JM, Dodds L, Andreou P. Severe respiratory syncytial virus infection in preterm infants and later onset of asthma. Pediatr Infect Dis J. 2019;38(11):1121-1125.
Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341-e348.
Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556-569.
Resch B, Kurath-Koller S, Eibisberger M, Zenz W. Prematurity and the burden of influenza and respiratory syncytial virus disease. World J Pediatr. 2016;12(1):8-18.
Mahant S, Parkin PC, Thavam T, et al. Rates in bronchiolitis hospitalization, intensive care unit use, mortality, and costs from 2004 to 2018. JAMA Pediatr. 2022;176(3):270-279.
Garcia-Maurino C, Moore-Clingenpeel M, Wallihan R, et al. Discharge criteria for bronchiolitis: an unmet need. Pediatr Infect Dis J. 2018;37(6):514-519.
Petrarca L, Nenna R, Frassanito A, et al. Acute bronchiolitis: influence of viral co-infection in infants hospitalized over 12 consecutive epidemic seasons. J Med Virol. 2018;90(4):631-638.
Brand HK, de Groot R, Galama JM, et al. Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. Pediatr Pulmonol. 2012;47(4):393-400.
Wishaupt JO, van der Ploeg T, de Groot R, Versteegh FG, Hartwig NG. Single- and multiple viral respiratory infections in children: disease and management cannot be related to a specific pathogen. BMC Infect Dis. 2017;17(1):62.
Calvo C, Garcia-Garcia ML, Blanco C, et al. Multiple simultaneous viral infections in infants with acute respiratory tract infections in Spain. J Clin Virol. 2008;42(3):268-272.
Richard N, Komurian-Pradel F, Javouhey E, et al. The impact of dual viral infection in infants admitted to a pediatric intensive care unit associated with severe bronchiolitis. Pediatr Infect Dis J. 2008;27(3):213-217.
Rodriguez DA, Rodriguez-Martinez CE, Cardenas AC, et al. Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region. Pediatr Pulmonol. 2014;49(3):269-276.
Kutsaya A, Teros-Jaakkola T, Kakkola L, et al. Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life. Epidemiol Infect. 2016;144(8):1622-1633.
Wong K, Robinson JL, Hawkes MT. Risk of repeated admissions for respiratory syncytial virus in a cohort of >10 000 hospitalized children. J Pediatric Infect Dis Soc. 2021;10(3):352-358.